Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesNeurology/NeurosurgeryBCBS-RI TOMAC Coverage Update | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

    Tonic Motor Activation (TOMAC) for Restless Legs Syndrome — Coverage Criteria

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - Rhode Island policy alerts

    Know when Blue Cross Blue Shield - Rhode Island releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Policy governing coverage determinations for bilateral peroneal nerve stimulation (TOMAC) to treat primary restless legs syndrome (RLS) refractory to medication for Blue Cross Blue Shield - Rhode Island members.

    Policy Summary
    PayerBlue Cross Blue Shield - Rhode Island
    PolicyTonic Motor Activation (TOMAC) for Restless Legs Syndrome — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeAdministrative update — no material clinical changes
    Effective DateJun 1, 2026
    Last ReviewFeb 18, 2026
    Next Review DateFeb 18, 2026
    Key ActionVerify member benefits and eligibility before providing services.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Not coveredCoverage stance

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    De Novo
    Regulatory status
    2 codesCodes not covered
    RCTs+metaEvidence

    Coverage Determination and Criteria

    Coverage determination for TOMAC as a treatment for RLS

    Covered when ALL of the following are met:

    Overall coverage stance: Tonic Motor Activation (TOMAC) is not covered for Medicare Advantage plans and is not medically necessary for Commercial products because the evidence is insufficient to determine improvement in net health outcome.

    Policy states TOMAC is indicated clinically only for moderate-to-severe primary RLS refractory to pharmacologic treatment, but coverage is denied based on evidence assessment.

    Clinical indication: Patient has moderate-to-severe primary restless legs syndrome (RLS) that is refractory to pharmacologic treatment.

    TOMAC is not a first-line therapy; it is intended for cases refractory to standard treatments such as iron supplementation, gabapentinoids, and behavioral measures.

    Therapy sequencing: Conventional first-line therapies (eg, iron supplementation, gabapentinoids, lifestyle modifications) have been attempted and were ineffective, not tolerated, or contraindicated.

    Clinical pathway describes TOMAC as indicated only after failure of pharmacologic treatment.

    Use of HCPCS codes A4544 and E0743 for bilateral peroneal nerve stimulation (TOMAC) is listed as not covered for Medicare Advantage plans and not medically necessary for Commercial products.

    For Commercial products, TOMAC for medication-refractory restless legs syndrome is considered not medically necessary because the evidence is insufficient to demonstrate improvement in net health outcome. The available literature includes randomized controlled trials, nonrandomized studies, and a systematic review/meta-analysis that showed some symptom and sleep quality benefits versus sham but were limited by small sample sizes, short follow-up, potential unblinding, and lack of long-term randomized data; these limitations prevent concluding durable clinical benefit.

    Billing and Coding

    Not covered / Not medically necessary codesHCPCSNot Covered
    A4544Electrode for external lower extremity nerve stimulator for restless legs syndrome
    E0743External lower extremity nerve stimulator for restless legs syndrome, each

    Provider Responsibilities and Billing Actions

    Note

    Prior Authorization

    Prior authorization is not applicable for this policy.

    Step Therapy

    Therapy Sequencing

    TOMAC (transcutaneous osseous magnetic stimulation) is not a first-line therapy. It is indicated only for moderate-to-severe primary restless legs syndrome (RLS) that is refractory to pharmacologic therapy; first-line options include iron supplementation, gabapentinoids, and lifestyle modifications.

    Documentation Required

    Verify Benefits and Eligibility

    Verify benefits and eligibility prior to providing services. Coverage may vary by contract; refer to the member's Evidence of Coverage / Subscriber Agreement or contact the provider call center for member-specific information.

    Clinical Background

    Restless legs syndrome (RLS) is a neurologic disorder characterized by an uncontrollable urge to move the legs, often accompanied by uncomfortable sensations and associated sleep disturbance. Patients commonly experience periodic limb movements during sleep, and standard management emphasizes pharmacologic therapies (for example, alpha-2-delta ligands or dopaminergic agents), iron repletion when indicated, and behavioral measures prior to consideration of device-based interventions such as TOMAC.

    Key Definitions

    inv-10: TOMAC — Tonic Motor Activation definition and key points
    DefinitionTonic Motor Activation (TOMAC): bilateral peroneal nerve stimulation using electrodes on the lower legs to deliver high-frequency stimulation to the common peroneal nerves, producing sustained low‑level tibialis anterior muscle contractions.
    Mechanism of actionStimulation activates the tibialis anterior muscle to mimic voluntary leg movements and sends afferent feedback to the central nervous system, potentially suppressing abnormal sensory signals that drive the urge to move.
    Clinical intentDesigned to reproduce movement-like activation (eg, walking/stretching) that can relieve RLS symptoms by modulating spinal and supraspinal pathways.
    Device targetingTargets the common peroneal nerves located near the fibula in the lower legs for tonic motor activation (distinct from sensory-focused TENS).
    Distinguishing featuresDiffers from TENS by targeting motor pathways with sustained, high-frequency bilateral stimulation aimed at tonic activation rather than pulsed sensory pain relief.
    Policy Summary
    PayerBlue Cross Blue Shield - Rhode Island
    PolicyTonic Motor Activation (TOMAC) for Restless Legs Syndrome — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeAdministrative update — no material clinical changes
    Effective DateJun 1, 2026
    Last ReviewFeb 18, 2026
    Next Review DateFeb 18, 2026
    Key ActionVerify member benefits and eligibility before providing services.
    SourceLink
    On This Page
    Coverage Determination and CriteriaBilling and CodingProvider Responsibilities and Billing ActionsClinical BackgroundKey Definitions
    Denial Risk

    Billing Denial Risk for Listed Codes

    Billing denial risk: the following codes will be considered not covered / not medically necessary for this indication and may be denied if billed for external lower extremity nerve stimulation for RLS.

    • A4544 — Electrode for external lower extremity nerve stimulator for restless legs syndrome
    • E0743 — External lower extremity nerve stimulator for restless legs syndrome, each
    inv-11: PLMD — Periodic limb movement disorder definition
    DefinitionPeriodic limb movement disorder (PLMD): periodic limb movements during sleep that occur without restless legs syndrome (RLS) or related disorders.
    Relation to RLSPLMS (periodic limb movements during sleep) commonly co-occur with RLS, but when PLMS occurs in the absence of RLS or other related disorders it is classified as PLMD.
    Clinical impactPLMD can contribute to sleep disturbance and impaired daytime functioning similar to RLS-associated periodic limb movements.